Insights

Strategic Partnerships Model Medicines has a history of collaboration with leading research institutions (Icahn School of Medicine at Mount Sinai and UCSD) to test antiviral candidates, indicating strong partner-fit potential for co-development, joint research programs, or sponsored studies to validate MDL-001 and related platforms.

AI-Driven Platform With Galileo and an ultra-large virtual screening platform, the company emphasizes scalable AI and computational drug discovery capabilities, presenting a sales angle for enterprise customers seeking accelerated hit discovery, platform licenses, or consulting services to augment internal pipelines.

Therapeutic Focus Active programs span infectious disease, oncology, and inflammation, targeting conserved molecular choke points, which suggests opportunities to position services or collaborations around broad-spectrum antiviral initiatives, novel BRD4 inhibition, or mechanism-based screening for multi-pathology therapeutics.

Early-Stage Signals Recent public appearances and updates at industry events, including AI convergence and global partnering conferences, along with ongoing lead candidate MDL-001 updates, indicate a readiness stage for strategic partnerships, licensing discussions, or investment conversations around platform-enabled drug discovery.

Financial Readiness Current revenue range and $22M in funding underscore a growing, mission-driven biotech with appetite for collaboration, co-development, or milestone-based agreements that align with its expansion plans and platform commercialization timelines.

Similar companies to Model Medicines

Model Medicines Tech Stack

Model Medicines uses 8 technology products and services including Twitter Ads, HubSpot Analytics, Linkedin Insight Tag, and more. Explore Model Medicines's tech stack below.

Media & News

Model Medicines's Email Address Formats

Model Medicines uses at least 1 email format:
Model Medicines Email FormatsExamplePercentage
First@modelmedicines.comJohn@modelmedicines.com
100%

Frequently Asked Questions

What is Model Medicines's official website and social media links?

Minus sign iconPlus sign icon
Model Medicines's official website is modelmedicines.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Model Medicines generate?

Minus sign iconPlus sign icon
As of November 2026, Model Medicines's annual revenue is estimated to be $1M - $10M.

What is Model Medicines's SIC code and NAICS code?

Minus sign iconPlus sign icon
Model Medicines's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Model Medicines have currently?

Minus sign iconPlus sign icon
As of November 2026, Model Medicines has approximately 15 employees across 2 continents, including North America and Asia. Key team members include Machine Learning Fellow: S. A., Plombier: G. K. and Customer Service Officer: S. R. R. Explore Model Medicines's employee directory with LeadIQ.

What industry does Model Medicines belong to?

Minus sign iconPlus sign icon
Model Medicines operates in the Biotechnology Research industry.

What technology does Model Medicines use?

Minus sign iconPlus sign icon
Model Medicines's tech stack includes Twitter Ads, HubSpot Analytics, Linkedin Insight Tag, Squarespace, Squarespace Commerce, Google Workspace, Google Tag Manager and Google Analytics.

What is Model Medicines's email format?

Minus sign iconPlus sign icon
Model Medicines's email format typically follows the pattern of First@modelmedicines.com. Find more Model Medicines email formats with LeadIQ.

How much funding has Model Medicines raised to date?

Minus sign iconPlus sign icon
As of November 2026, Model Medicines has raised $22M in funding. The last funding round occurred on Nov 14, 2025.

When was Model Medicines founded?

Minus sign iconPlus sign icon
Model Medicines was founded in 2019.
Model Medicines logo

Model Medicines

Biotechnology ResearchCalifornia, United States11-50 Employees

Model Medicines is a La Jolla, California-based biotechnology research company that uses AI to model chemistry and human biology to accelerate drug discovery. Founded in 2019, it sits at the intersection of data science, biology, and drug development, pursuing a pipeline of 67 validated assets in cellular disease models across 12 therapeutic targets, including oncology, virology, gastric, neurological, and weight disorders. Its customers are pharmaceutical researchers and biotech partners seeking more efficient early-stage drug discovery and translational insights. The company has pursued collaborations with academic medical centers to test antiviral potential, including partnerships with Icahn School of Medicine at Mount Sinai and UCSD, and it has highlighted a lead candidate, MDL-001, at industry events. In addition, Model Medicines launched Galileo, an AI-based drug discovery platform, in 2022 to support discovery for hematological diseases and solid tumors.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
11-50

Section iconFunding & Financials

  • $22M

    Model Medicines has raised a total of $22M of funding over 4 rounds. Their latest funding round was raised on Nov 14, 2025 as a Venture Round.

  • $1M - $10M

    Model Medicines's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.